{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:52:05Z","timestamp":1788209525364,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00367","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T13:03:50Z","timestamp":1591880630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism"],"prefix":"10.3389","volume":"11","author":[{"given":"Rosario","family":"Le Moli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualino","family":"Malandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Lo Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"B1","first-page":"492","article-title":"Treatment of thyrotoxicosis","volume-title":"Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text.","author":"Cooper","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves' disease: introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"Wemeau","year":"2018","journal-title":"Ann Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves' Disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/cncr.22635","article-title":"Increased cancer incidence after radioiodine treatment for hyperthyroidism","volume":"109","author":"Metso","year":"2007","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0173722","DOI":"10.1371\/journal.pone.0173722","article-title":"Effect of excess iodine intake on thyroid diseases in different populations: a systematic review and meta-analyses including observational studies","volume":"12","author":"Katagiry","year":"2017","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2265.2003.01862.x","article-title":"Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease","volume":"59","author":"Strieder","year":"2003","journal-title":"Clin Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1210\/jc.85.3.1038","article-title":"Age and gender predict the outcome of treatment for Graves' hyperthyroidism","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves'disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1586\/17446651.1.1.91","article-title":"Antithyroid drug therapy of Graves' hyperthyroidism: realistic goals and focus on evidence","volume":"1","author":"Laurberg","year":"2006","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1089\/thy.2015.0647","article-title":"Does immunosuppressive therapy improve outcomes in Graves' disease?","volume":"26","author":"Struja","year":"2016","journal-title":". Thyroid."},{"key":"B17","first-page":"401","article-title":"Effect of carbimazole and dexamethasone on TSH bond (TBII) inhibiting immunoglobulins in Graves-Basedow disease","volume":"183","author":"Olbios","year":"1988","journal-title":"Rev Clin Esp"},{"key":"B18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.52.735","article-title":"Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti \u2013 TSH receptor antibodies and clinical outcome in Graves' disease","volume":"52","author":"Kubota","year":"2005","journal-title":"Endocr J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.curtheres.2008.08.004","article-title":"Comparison of methimazole\/idrocortisone ointment with oral methimazole in patients with Graves' disease: a prospective, randomized, open label, parallel group, 18-month study","volume":"69","author":"Chen","year":"2008","journal-title":"Curr Ther Res Clin Exp."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1210\/jc.2009-1252","article-title":"Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone","volume":"94","author":"Mao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/ European Group on Graves' Orbitopathy Guidelines for the management of Graves' Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' Orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","article-title":"European Thyroid Association guideline for the management of Graves' hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoids pulse therapy in patients with Graves' ophthalmopathy","volume":"14","author":"Marin\u00f3","year":"2004","journal-title":"Thyroid."},{"key":"B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-13-0811","article-title":"Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000\u20132010","volume":"170","author":"Mohlin","year":"2014","journal-title":"Eur J Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1210\/jc.2018-01738","article-title":"Age may influence the impact of TRAbs on thyroid function and relapse-risk in patients with Graves disease","volume":"104","author":"Bano","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12020-018-1785-z","article-title":"Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value","volume":"63","author":"Garc\u00eda-Mayor","year":"2019","journal-title":"Endocrine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3803\/EnM.2019.34.1.29","article-title":"Graves' Disease: can it be cured?","volume":"34","author":"Wiersinga","year":"2019","journal-title":"Endocrinol Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"12681","DOI":"10.1093\/nar\/gkx865","article-title":"Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone","volume":"45","author":"Enuka","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.1074\/jbc.R117.777318","article-title":"Glucocorticoid and cytokine crosstalk: feedback, feedforward, and co-regulatory interactions determine repression or resistance","volume":"292","author":"Newton","year":"2017","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-genomic effects of glucocorticoids: an updated view","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/mp.2017.35","article-title":"Epigenetic programming by stress and glucocorticoids along the human lifespan","volume":"22","author":"Zannas","year":"2017","journal-title":"Mol Psychiatry"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T13:03:53Z","timestamp":1591880633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":35,"alternative-id":["10.3389\/fendo.2020.00367"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00367","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"article-number":"367"}}